Iridex Corporation announced the grant of the European Patent EP 3009093, entitled “Laser System with Short Pulse Characteristics and its Methods of Use”. This groundbreaking patent further protects Iridex’s intellectual property encompassing laser systems in ophthalmology and related fields, for technology that enhances safe and effective laser treatments. Iridex is the exclusive provider of MicroPulse devices that utilize the patented technology. Revolutionizing Eye Care with Precision and Safety The patented technology delivers a laser system capability for delivering short, controlled-width pulse trains. This technology is designed to minimize the risk of full-thickness retinal damage and vision loss, a common concern with traditional laser treatments with numerous clinical studies demonstrating its safety and efficacy in retina and glaucoma applications and beyond.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IRIX:
- Iridex Announces First Patient Enrollment in MicroPulse® TLT Clinical Study Conducted in Collaboration with Imperial College Healthcare NHS Trust
- Iridex announces first patient enrollment in MicroPulse TLT study
- Iridex Launches New Iridex 532® and Iridex 577® Lasers in US Market Marking 35 Years of Laser Innovation in Treating Retina Disorders & Glaucoma
- Iridex Confirms Medicare Administrative Contractors Retired Local Coverage Determinations that Restricted Cyclophotocoagulation